Last updated on October 2018

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Brief description of study

The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

Clinical Study Identifier: NCT02872714

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Mount Sinai Medical Center
Miami Beach, FL United States
  Connect »